Literature DB >> 21291955

LC, a novel estrone-rhein hybrid compound, concurrently stimulates osteoprotegerin and inhibits receptor activator of NF-κB ligand (RANKL) and interleukin-6 production by human osteoblastic cells.

Yue Wang1, Ling Zhi Li, Yong Liang Zhang, Ya Qin Zhu, Jian Wu, Wei Jia Sun.   

Abstract

Estrogen analogues are promising drugs for postmenopausal osteoporosis, but because of their possible side effects such as increased risk of cancer, estrogens which exert their estrogenic effects selectively on bone are desired. It has been shown that rhein inhibits osteoclast formation and bone resorption activity and has an antitumor role in several types of cancers. Having found that rhein had high affinity for the bone mineral, we synthesized estrone-rhein hybrid compounds and confirmed that one of these hybrid compounds, LC, exhibited a selective profile in the bone and prevented bone loss but had no effect on endometrium growth in ovariectomized rats. However, the mechanisms underlying its actions on human bone cells have not been well defined. Here we show that LC concurrently stimulates osteoprotegerin (OPG) and inhibits receptor activator of nuclear factor-κB ligand (RANKL) and Interleukin-6 (IL-6) production by human osteoblastic MG-63 cells containing two estrogen receptor (ER) isotypes. Treatment with the ER antagonist ICI 182,780 abrogates the above actions of LC on osteoblast-derived cells. Using small interfering double-stranded RNAs (siRNA) technology, we further demonstrate that the effects of LC on IL-6 production are mediated by both ERα and ERβ but those on OPG and RANKL expression primarily by ERα. Furthermore, we also demonstrate that LC functions at least partially through activation of the classic estrogen response element (ERE) pathway as well as Ras/MEK/ERK and PI3K/Akt signaling. The effect of LC on bone is due to not only its estrogenic activity but also action of its rhein moiety. Also, this compound shows much weaker effect on breast epithelial cell growth than that of estrone. Therefore, using rhein for conjugating compounds is a promising method of effectively targeting estrogens to the bone.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21291955     DOI: 10.1016/j.mce.2011.01.018

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  4 in total

1.  Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells.

Authors:  M Doyard; N Fatih; A Monnier; M L Island; M Aubry; P Leroyer; R Bouvet; G Chalès; J Mosser; O Loréal; P Guggenbuhl
Journal:  Osteoporos Int       Date:  2012-01-12       Impact factor: 4.507

2.  Treatment effect of Bushen Huayu extract on postmenopausal osteoporosis in vivo.

Authors:  Lu Ouyang; Qiufang Zhang; Xuzhi Ruan; Yibin Feng; Xuanbin Wang
Journal:  Exp Ther Med       Date:  2014-04-02       Impact factor: 2.447

3.  Effects of low doses of estrone on the proliferation, differentiation and mineralization of osteoprecursor cells.

Authors:  Jun-Beom Park
Journal:  Exp Ther Med       Date:  2012-08-03       Impact factor: 2.447

4.  The natural agent rhein induces β-catenin degradation and tumour growth arrest.

Authors:  Shu Liu; Jiao Wang; Ting Shao; Peiying Song; Qingbin Kong; Hui Hua; Ting Luo; Yangfu Jiang
Journal:  J Cell Mol Med       Date:  2017-10-11       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.